IFORELS Formalizes as Delaware C-Corp with Strategic Founder Capital, Positioning for US Healthcare Growth

In early 2022, founder Vlad Panin committed approximately $200,000 of his personal capital to formalize IFORELS Inc. On May 3, 2022, the company officially incorporated in Delaware and closed an undisclosed pre-seed round the same day. A Bay Area address was established alongside the incorporation. This modest yet deliberate capitalization marked a pivotal transition from the previous year’s rapid experimentation phase to a professionally structured entity ready for scaled operations in the US market.

The choice of Delaware as the jurisdiction was strategic and pragmatic. Delaware has long been the preferred state for incorporation among US companies, particularly technology and healthcare startups, due to its well-established corporate laws, business-friendly courts, and investor protections. More than two-thirds of Fortune 500 companies are incorporated there, creating a predictable legal environment that simplifies governance, fundraising, and compliance. The Bay Area address further signaled seriousness to both enterprise buyers and institutional investors. At the time, US healthcare organizations and financial institutions routinely required domestic incorporation and a US presence on vendor forms to satisfy procurement and regulatory checklists. By addressing these requirements upfront, IFORELS removed potential barriers that could otherwise disqualify the company during competitive bidding processes.

The $200,000 figure, while relatively small by Silicon Valley standards, carried symbolic and practical weight. It was never intended as multi-year runway but as clear evidence of founder commitment. Panin has referenced the amount consistently in interviews as the kind of check a founder writes when he intends to be the largest creditor of his own company until external capital validates the vision. Combined with the undisclosed pre-seed round closed on the same day, the capital supported operations through the end of 2022. By that point, the company’s first revenue-generating product — the AI medical-coding bot — was already producing invoices and converting early pilots into paying customers.

This formalization built directly on the momentum from 2021, when IFORELS had shipped eleven products and cultivated deep enterprise relationships through open-source collaboration. The Delaware C-corp structure and US headquarters enabled the company to engage more effectively with hospitals, insurers, and large healthcare systems that demand rigorous vendor due diligence. Vlad Panin’s extensive background in regulated enterprise environments informed every structural decision. Having founded Orkin, an Eastern European systems-integration firm, and delivered complex United Nations Smart City programs for municipalities across the European Union, he understood the importance of institutional-grade governance. His subsequent experience running enterprise IT for industrial-water companies under Japanese parent governance further sharpened his instinct for building organizations that large buyers and sophisticated investors would trust.

The May 3, 2022 filing was not merely administrative paperwork. It represented a professionalization milestone that aligned legal structure, headquarters location, and capital with the company’s healthcare AI ambitions. From this foundation, IFORELS could confidently pursue deeper integration with electronic health record systems and position itself for the institutional capital and commercial contracts that would follow. The move exemplified the same disciplined execution that defined the company’s first year: focus on the unsexy but essential elements of the stack, prioritize long-term credibility over short-term optics, and build infrastructure that supports sustainable growth. By mid-2022, with a solid corporate vehicle in place, IFORELS was fully prepared to accelerate its transition into a specialized healthcare AI leader.